



IFW

MAIL STOP: PCT  
Attorney Docket No.: 27581

In re Application of:

CAHILL et al.

Intl. Application No.: PCT/EP2005/001567

Application No.: 10/589,487

Intl. Filing Date: February 16, 2005

Filing Date: August 15, 2006

Title: **DIAGNOSTIC MARKER FOR CANCER**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


- 1) Supplemental Information Disclosure Statement;
- 2) PTO Form-1449 with 19 references cited;
- 3) Copies of 18 of the 19 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account Number 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

December 4, 2006

By:

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,965  
Tanya E. Harkins. Reg. No. 52,993  
Customer No. 20529

ct



MAIL STOP: PCT  
Attorney: GMN / TEH  
Attorney Docket No.: 27581U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

CAHILL et al.

Intl. Application No.: PCT/EP2005/001567

Application No.: 10/589,487

Intl. Filing Date: February 16, 2005

Filing Date: August 15, 2006

Title: **DIAGNOSTIC MARKER FOR CANCER**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- a. ☐ [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. ☐ [ ] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.  
The enclosed statement is accompanied by [check one]:  
☐ [ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or  
☐ [ ] ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.  
☐ Certification report(e) below; and  
☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,  
or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached, with a completed Form PTO-1449, as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

December 4, 2006

By:

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,695  
Tanya E. Harkins, Reg. No. 52,993  
Customer No. 20529

ct



**PTO FORM-1449**  
**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE**  
**CITATION**

In re Application of:  
 CAHILL et al.

Application No:  
 10/589,487

Filed:  
 August 15, 2006

Examiner:  
 UNKNOWN

Art Unit:  
 UNKNOWN

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
	A1	6,645,465	11 Nov 2003	Hanash et al.	06 Aug 1999
	A2				

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number	Publication Date	Country	Translation
	A3				
	A4				

**OTHER**

	A5	Oh et al., "Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy". <u>Nature</u> , vol. 429, pp.629-635, 2004.
	A6	Oh et al., "Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy" [E. Supp. 1]. <u>Nature</u> , vol. 429, pp.629-635, 2004.
	A7	H. He, "HS1 and EMS1". <u>Gan To Kagaku Ryoho</u> , vol. 24, pp.1448-1453, 1997.
	A8	Ko et al., "Role of Ubiquitin Associated with Protein-disulfide Isomerase in the Endoplasmic Reticulum in Stress-induced Apoptotic Cell Death". <u>J. of Bio. Chem.</u> , vol. 277, pp.35386-35392, 2002.
	A9	Horiuchi et al., "Molecular cloning and multifunctions of membrane-associated 3,5,3'-triiodo-L-thyronine binding protein with protein disulfide isomerase activity". <u>Nippon Rinsho</u> , vol. 52, pp.890-895, 1994.
	A10	Peyrl et al., "Protein profiles of medulloblastoma cell lines DAOY and D283: Identification of tumor-related proteins and principles". <u>Proteomics</u> , vol. 3, pp.1781-1800, 2003.
	A11	Hoffman et al., "Interactions of Benzodiazepine Derivatives with Annexins". <u>J. of Bio. Chem.</u> , v. 273, pp. 2885-2894, 1998.
	A12	Wang et al., "Annexin-mediated Ca <sup>2+</sup> Influx Regulates Growth Plate Chondrocyte Maturation and Apoptosis". <u>J. of Bio. Chem.</u> , vol. 278, pp.3762-3769, 2003.
	A13	Chung et al., "Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Heat Shock Protein 90 Inhibitor 17-Allylamino,17-Demethoxygeldanamycin (17AAG) in Human Colon Cancer Models". <u>J. of Nat. Canc. Inst.</u> , vol. 95, pp.1624-1633, 2003.
	A14	Bondanza et al. "Inhibition of Phosphatidylserine Recognition Heightens the Immunogenicity of Irradiated Lymphoma Cells In Vivo". <u>J. Exp. Med.</u> , vol. 200, pp.1157-1165, 2004.
	A15	Alaiya et al., "Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry". <u>Cell. Mol. Life Sci.</u> , vol. 58, pp.307-311, 2001.
	A16	Seidita et al., "Differential gene expression in p53-mediated G <sub>1</sub> arrest of human fibroblasts after $\gamma$ -irradiation or N-phosphoacetyl-L-aspartate treatment". <u>Carcinogenesis</u> , vol. 21, pp.2203-2210, 2000.
	A17	R.H. Ashley, "Challenging accepted ion channel biology: p64 and the CLIC family of putative intracellular anion channel proteins (Review)". <u>Molecular Membrane Bio.</u> , vol. 20, pp.1-11, 2003.
	A18	MacDonald et al., "Proteomic Survey of PKG-Targets Reveals a Novel Regulator of Smooth Muscle Contractility" [Abstract]. <u>Molecular and Cellular Proteomics</u> , vol. 2, pp.795, 2003.
	A19	"Brouard et al., "Urinary Excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma". <u>Melanoma Research</u> , vol. 12, pp.627-631, 2002.

<b>PTO FORM-1449</b> <b>SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE</b> <b>CITATION</b>		In re Application of: CAHILL et al.	
		Application No: 10/589,487	Filed: August 15, 2006
		Examiner: UNKNOWN	Art Unit: UNKNOWN
	A20	Cahill et al., "Analysis of relative isotopologue abundances for quantitative profiling of complex protein mixtures labeled with the acrylamide/D <sub>3</sub> -acrylamide alkylation tag system". <u>Rapid Commun. Mass Spectrom.</u> , vol. 17, pp.1283-1290, 2003.	
	A21	Vogt et al., "Protein abundance quantification in embryonic stem cells using incomplete metabolic labeling with <sup>15</sup> N amino acids, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and analysis of relative isotopologue abundances of peptides". <u>Rapid Commun. Mass Spectrom.</u> , vol. 17, pp.1273-1282, 2003.	
	A22	Shekouh et al., "Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma". <u>Proteomics</u> , vol. 3 pp. 1988-2001, 2003.	
Examiner		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			